The role of Adiponectin and Leptin in Colorectal Cancer and Adenoma: a systematic review and meta-analysis.

IF 3.4 2区医学 Q2 ONCOLOGY

BMC Cancer Pub Date : 2025-05-30 DOI:10.1186/s12885-025-14362-y

Iman Elahi Vahed, Mahsa Moshgelgosha, Abdolmajid Kor, Mona Minadi, Faezeh Ebrahimi, Aylar Azhdarian, Mobina Arjmandi, Aida Alamdar, Maede Zare, Niloufar Shabani, Hossein Soltaninejad, Mohammad Rahmanian

{"title":"The role of Adiponectin and Leptin in Colorectal Cancer and Adenoma: a systematic review and meta-analysis.","authors":"Iman Elahi Vahed, Mahsa Moshgelgosha, Abdolmajid Kor, Mona Minadi, Faezeh Ebrahimi, Aylar Azhdarian, Mobina Arjmandi, Aida Alamdar, Maede Zare, Niloufar Shabani, Hossein Soltaninejad, Mohammad Rahmanian","doi":"10.1186/s12885-025-14362-y","DOIUrl":null,"url":null,"abstract":"Background: Colorectal cancer ranks as the third most frequently diagnosed cancer globally. Adipokines, including adiponectin and leptin, are believed to play a vital role in the development and progression of tumors. This study aimed to clarify the association between circulating adiponectin and leptin concentrations and the risk of colorectal cancer and adenoma.Methods: A detailed literature review was conducted in different databases, including Google Scholar, Web of Science, Scopus, and PubMed. Articles measuring serum concentrations of adiponectin and leptin in colorectal adenoma or cancer patients were analyzed. Pooled odds ratios (ORs) and their related 95% confidence intervals (CIs) were estimated through a random-effects meta-analysis.Results: In total, 30 articles were analyzed. According to the meta-analysis, higher adiponectin concentrations were inversely linked to a reduced CRC risk (OR: 0.85, 95% CI: 0.74-0.96), particularly in men. However, no notable connection was detected between higher leptin concentrations and risk of CRC (OR: 1.12, 95% CI: 0.96-1.31). In subgroup analyses, BMI adjustment reinforced the negative association between higher adiponectin levels and risk of CRC, while insulin adjustment yielded non-significant results. Additionally, higher leptin levels revealed a meaningful relationship with colorectal adenoma risk (OR: 1.39, 95% CI: 1.06-1.84), whereas higher levels of adiponectin were not significantly linked to adenoma (OR: 0.79, 95% CI: 0.46-1.36).Conclusion: According to this meta-analysis, elevated adiponectin concentrations may play a protective role against CRC, while leptin could potentially contribute to an elevated colorectal adenoma risk. Further studies are required to explore the potential mechanisms underlying adipokine-mediated colorectal carcinogenesis.","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"968"},"PeriodicalIF":3.4000,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12123994/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12885-025-14362-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Colorectal cancer ranks as the third most frequently diagnosed cancer globally. Adipokines, including adiponectin and leptin, are believed to play a vital role in the development and progression of tumors. This study aimed to clarify the association between circulating adiponectin and leptin concentrations and the risk of colorectal cancer and adenoma.

Methods: A detailed literature review was conducted in different databases, including Google Scholar, Web of Science, Scopus, and PubMed. Articles measuring serum concentrations of adiponectin and leptin in colorectal adenoma or cancer patients were analyzed. Pooled odds ratios (ORs) and their related 95% confidence intervals (CIs) were estimated through a random-effects meta-analysis.

Results: In total, 30 articles were analyzed. According to the meta-analysis, higher adiponectin concentrations were inversely linked to a reduced CRC risk (OR: 0.85, 95% CI: 0.74-0.96), particularly in men. However, no notable connection was detected between higher leptin concentrations and risk of CRC (OR: 1.12, 95% CI: 0.96-1.31). In subgroup analyses, BMI adjustment reinforced the negative association between higher adiponectin levels and risk of CRC, while insulin adjustment yielded non-significant results. Additionally, higher leptin levels revealed a meaningful relationship with colorectal adenoma risk (OR: 1.39, 95% CI: 1.06-1.84), whereas higher levels of adiponectin were not significantly linked to adenoma (OR: 0.79, 95% CI: 0.46-1.36).

Conclusion: According to this meta-analysis, elevated adiponectin concentrations may play a protective role against CRC, while leptin could potentially contribute to an elevated colorectal adenoma risk. Further studies are required to explore the potential mechanisms underlying adipokine-mediated colorectal carcinogenesis.

查看原文本刊更多论文

脂联素和瘦素在结直肠癌和腺瘤中的作用：系统回顾和荟萃分析。

背景：结直肠癌是全球第三大最常诊断的癌症。脂肪因子，包括脂联素和瘦素，被认为在肿瘤的发生和发展中起着至关重要的作用。本研究旨在阐明循环脂联素和瘦素浓度与结直肠癌和腺瘤风险之间的关系。方法：在谷歌Scholar、Web of Science、Scopus、PubMed等数据库中进行详细的文献综述。分析了结直肠腺瘤或肿瘤患者血清脂联素和瘦素浓度测定的文章。通过随机效应荟萃分析估计合并优势比（ORs）及其相关的95%置信区间（ci）。结果：共分析30篇文献。根据荟萃分析，较高的脂联素浓度与降低结直肠癌风险呈负相关（OR: 0.85, 95% CI: 0.74-0.96），尤其是在男性中。然而，高瘦素浓度与CRC风险之间没有明显的联系（OR: 1.12, 95% CI: 0.96-1.31）。在亚组分析中，BMI调整强化了高脂联素水平与结直肠癌风险之间的负相关，而胰岛素调整则没有显著结果。此外，较高的瘦素水平显示与结直肠腺瘤风险有意义的关系（OR: 1.39, 95% CI: 1.06-1.84），而较高的脂联素水平与腺瘤没有显著联系（OR: 0.79, 95% CI: 0.46-1.36）。结论：根据这项荟萃分析，脂联素浓度升高可能对结直肠癌起保护作用，而瘦素可能导致结直肠腺瘤风险升高。需要进一步的研究来探索脂肪因子介导的结直肠癌发生的潜在机制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMC Cancer 医学-肿瘤学

CiteScore

6.00

自引率

2.60%

发文量

1204

审稿时长

6.8 months

期刊介绍： BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.